Diarrhea on a GLP-1: how common, and how long it lasts
Reviewed 10 sourcesPublished by PepVault
Diarrhea on Ozempic, Wegovy, Mounjaro and Zepbound: each label's rate by dose against placebo, when it starts, how long a bout lasts, and what helps.

- Last reviewed
- Sources
- 10
- Questions
- 7
- Compounds
- 3
The short answer
Diarrhea is one of the most common side effects of Ozempic, Wegovy, Mounjaro and Zepbound. In the weight trials it affected 30% on Wegovy 2.4 mg and 19% to 23% on Zepbound, against 16% and 8% on placebo. On semaglutide a bout lasted a median of 3 days, most came during the dose climb, and few people stopped over it. Steady fluids and plain food help.
Evidence: FDA prescribing information for all four medicines, built on randomized placebo-controlled trials in people; trial registry results from STEP 1, SURMOUNT-1 and SURMOUNT-5; two sponsor-funded analyses of the trials after the fact for timing and duration; and an expert consensus for the eating advice.

How common is diarrhea on Ozempic, Wegovy, Mounjaro and Zepbound?
Common on all four, and clearly more common at the weight-loss doses. Ozempic and Wegovy are semaglutide; Mounjaro and Zepbound are tirzepatide. Each US label counts the share of people in its placebo-controlled trials who reported diarrhea at least once, set against a placebo group on a dummy shot1234:
| Medicine and dose | Trials behind the number | Diarrhea on the drug | Diarrhea on placebo |
|---|---|---|---|
| Ozempic 0.5 mg | 2 type 2 diabetes trials, 32.9 weeks on average | 8.5% | 1.9% |
| Ozempic 1 mg | The same 2 trials | 8.8% | 1.9% |
| Mounjaro 5 mg | 2 type 2 diabetes trials, 36.6 weeks on average | 12% | 9% |
| Mounjaro 10 mg | The same 2 trials | 13% | 9% |
| Mounjaro 15 mg | The same 2 trials | 17% | 9% |
| Wegovy 2.4 mg | 3 weight trials, up to 68 weeks | 30% | 16% |
| Zepbound 5 mg | 2 weight trials, up to 72 weeks | 19% | 8% |
| Zepbound 10 mg | The same 2 trials | 21% | 8% |
| Zepbound 15 mg | The same 2 trials | 23% | 8% |
The placebo column matters: people get diarrhea in ordinary life too, and the gap between the two columns is the part the medicine adds. Tirzepatide's rate rises with each dose step. The labels warn that rates from different trials cannot be compared directly, because the people, doses and trial lengths differ13. When both drugs ran in one trial for 72 weeks (SURMOUNT-5), at their top weight doses or the highest each person tolerated, diarrhea was a tie: 88 of 374 people on tirzepatide and 88 of 376 on semaglutide, 23.5% and 23.4%10.
Wegovy's 7.2 mg dose does not list diarrhea among the effects that were more common on it than on both 2.4 mg and placebo. The Wegovy pill (25 mg) had side effects of similar types and rates to the 2.4 mg shot. In teenagers on Wegovy, diarrhea affected 22% against 19% on placebo2.

Is diarrhea on a GLP-1 serious?
Rarely. In the STEP 1 to 3 weight trials, 98.1% of all stomach side effects on semaglutide 2.4 mg were mild or moderate and 99.5% were not serious5. In STEP 1, one person of the 1,306 on semaglutide had diarrhea counted as a serious event8. Few stopped over it: 0.7% of people on Wegovy left the trials because of diarrhea, against 0.1% on placebo2.
The one real risk is fluid loss. All four labels note that kidney injury from dehydration has been reported after approval, mostly in people whose nausea, vomiting or diarrhea dried them out, and they ask people to take care not to run short on fluids1234.
When does GLP-1 diarrhea start?
During the dose climb, called titration: the slow step-up from a starting dose every four weeks or more. All four labels say most nausea, vomiting and diarrhea came during dose escalation, and the Mounjaro and Zepbound labels add that it decreased over time1234.
The STEP trials traced the timing week by week. Among people on semaglutide 2.4 mg, the share with diarrhea at any one time peaked at about week 20, just after the climb reached the full dose at week 16, and fell after that, while staying above placebo through week 68. Almost everyone who had a stomach side effect had their first one in the climbing weeks5. Tirzepatide follows the same arc: in the four SURMOUNT trials, people who needed an anti-diarrhea medicine most often first took it in the first 24 weeks, the stretch that held the climb6.
PepVault's dose log keeps each weekly shot with its date and the step-ups your prescriber set, as you enter them, so a loose week can be matched to the step before it. Log it in PepVault
How long does diarrhea last on a GLP-1?
About three days per bout. In the pooled STEP 1 to 3 analysis, each episode was timed from start to end: the median, the middle value, was 3 days on semaglutide 2.4 mg, similar to placebo5. What the medicine changes is how many people get it, not how long a bout lasts. The trial registries also count every bout reported, so we divided those counts by the number of people who had any, to show how often it came back8910:
| Trial and group | People with diarrhea | Bouts reported | Bouts per person who had it (our division) |
|---|---|---|---|
| STEP 1, semaglutide 2.4 mg (75 weeks) | 411 of 1,306 (31.5%) | 765 | 1.9 |
| STEP 1, placebo | 104 of 655 (15.9%) | 138 | 1.3 |
| SURMOUNT-1, tirzepatide 5 mg (up to 193 weeks) | 128 of 630 (20.3%) | 209 | 1.6 |
| SURMOUNT-1, tirzepatide 10 mg | 143 of 636 (22.5%) | 281 | 2.0 |
| SURMOUNT-1, tirzepatide 15 mg | 149 of 630 (23.7%) | 326 | 2.2 |
| SURMOUNT-1, placebo | 51 of 643 (7.9%) | 90 | 1.8 |
| SURMOUNT-5, tirzepatide (72 weeks) | 88 of 374 (23.5%) | 227 | 2.6 |
| SURMOUNT-5, semaglutide | 88 of 376 (23.4%) | 212 | 2.4 |
So across a year or more, the people on a GLP-1 who got diarrhea had it about two times on average (1.6 to 2.6), and the people on placebo who got it had it 1.3 to 1.8 times. Read each trial on its own: the time windows differ, SURMOUNT-1's count runs to week 193 because people with prediabetes stayed on for three years, and SURMOUNT-5 was open-label, so everyone knew which drug they took910. No primary source we found gives a per-bout length for tirzepatide.
Why do GLP-1s cause diarrhea?
The gut itself carries GLP-1 receptors, and these medicines change how fast food moves through it. The STEP analysis's authors write that changes in the speed of the lower gut may explain both diarrhea and constipation, and that the proof is still thin5. A Spanish expert panel adds a pattern across the drug class: the long-acting weekly shots bring less nausea and vomiting but more diarrhea than the older short-acting ones, which fits a steadier effect on the gut's receptors7.
Diarrhea is not what makes the weight come off. Of the extra weight lost on semaglutide 2.4 mg over placebo, under one percentage point was explained by stomach side effects5; for tirzepatide, nausea, vomiting, diarrhea and indigestion together accounted for at most 3.1% of the weight lost6. A calm gut is not a sign that the dose has stopped working.
What helps with diarrhea on a GLP-1?
Fluids first, then plain food. The labels ask for fluids1234, and the expert panel's recommendations for diarrhea on a GLP-1 give the rest7:
- Drink generously through the day, in small sips, and more on every loose day.
- Eat smaller meals, and stop as soon as you feel full.
- Choose plain food cooked by baking, grilling or boiling, such as chicken broth, rice, carrots and very ripe fruit without the skin.
- Leave out dairy, coffee, alcohol, soft drinks and very hot or very cold food until it settles.
- Skip sugar-free sweets and gum with sweeteners ending in "-ol", such as sorbitol, xylitol, mannitol and maltitol.
- Cut back on high-fibre food such as whole grains, beans, lentils, cabbage and skin-on fruit for a while, then bring it back gradually as you improve.
- Keep a short food diary to spot what makes it worse.
If it keeps coming back despite these steps, the panel lists options for the prescriber: a probiotic or an anti-diarrhea medicine such as loperamide, a slower climb, with more time on the lower dose (their worked example), and a lower metformin dose for people who take it, since a GLP-1 can make metformin's own diarrhea worse7. The Wegovy label tells prescribers to consider waiting four more weeks before the next step if a dose is not tolerated2. Every one of these is your prescriber's decision. In the SURMOUNT-1 to -3 trials, 5.2% to 9.3% of people on tirzepatide used an anti-diarrhea medicine, against 1.2% to 2.2% on placebo6.
Commonly reported: loose stools in the weeks after the first shot or a step-up, settling within days. In the open write-ups counted on our reports pages, 4 of 41 people on semaglutide and 1 of 77 on tirzepatide mentioned diarrhea.
When to get help Tell your prescriber right away if diarrhea does not go away, or if you cannot keep up with the fluids you are losing: the labels ask for that call because dehydration can lead to kidney problems1234.
How do I keep track of diarrhea on a GLP-1?
Write down the day it starts, how strong it is, what you ate and which dose you were on. A few weeks of notes show whether it gathers after each step-up and fades in days, as in the trials, or keeps going, which is the pattern to bring to your prescriber.
PepVault's side-effect log records each symptom with the compound, a severity from minimal to very severe, the date and a note. On tirzepatide, diarrhea is one tap in the quick list. Log it in PepVault
The full side-effect picture for each medicine, nausea and constipation included, is in our guides to Ozempic and Wegovy side effects, Mounjaro and Zepbound side effects, and semaglutide against tirzepatide.
Sources
- OZEMPIC (semaglutide) injection prescribing information, DailyMed (SPL version 20; label updated June 1, 2026, published on DailyMed June 10, 2026). Sections 5.6, 6.1 (Table 1), 17 and the Medication Guide. dailymed.nlm.nih.gov
- WEGOVY (semaglutide) injection and tablets prescribing information, DailyMed (SPL version 19; label updated June 18, 2026, published on DailyMed June 30, 2026). Sections 2.2, 5, 6.1 (Tables 3, 4 and 5), 17 and the Medication Guide. dailymed.nlm.nih.gov
- MOUNJARO (tirzepatide) injection prescribing information, DailyMed (SPL version 40; label updated August 27, 2026, published on DailyMed September 2, 2026). Sections 5, 6.1 (Table 1), 7.2, 17 and the Medication Guide. dailymed.nlm.nih.gov
- ZEPBOUND (tirzepatide) injection prescribing information, DailyMed (SPL version 40; label updated August 28, 2026, published on DailyMed September 2, 2026). Sections 5.3, 6.1 (Table 1), 7.2, 17 and the Medication Guide. dailymed.nlm.nih.gov
- Wharton S et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24:94-105. PubMed 34514682
- Rubino DM et al. Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials. Diabetes Obes Metab. 2025;27:1826-1835. PubMed 39789843
- Gorgojo-Martínez JJ et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2023;12:145. PubMed 36614945
- ClinicalTrials.gov NCT03548935 (STEP 1; sponsor Novo Nordisk A/S). Results: adverse events, week 0 to 75. clinicaltrials.gov
- ClinicalTrials.gov NCT04184622 (SURMOUNT-1; sponsor Eli Lilly and Company). Results: adverse events, baseline up to week 193. clinicaltrials.gov
- ClinicalTrials.gov NCT05822830 (SURMOUNT-5; sponsor Eli Lilly and Company). Results: adverse events, baseline up to week 72. clinicaltrials.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.